Genticel announces positive DSMB recommendation for ProCervix Phase 2 study in women with HPV

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces today that the Data and Safety Monitoring Board, an independent committee of experts which monitors safety data every six months during the study, met as scheduled on January 22nd. It recommended the RHEIA-VAC study proceed without any modifications.



from The Medical News http://ift.tt/1JzHQLs